MedPath
HSA Approval

TIDOMET FORTE TABLET

SIN12575P

TIDOMET FORTE TABLET

TIDOMET FORTE TABLET

July 31, 2004

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD
Licence HolderZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

N04BA02

levodopa and decarboxylase inhibitor

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

TORRENT PHARMACEUTICALS LTD

Active Ingredients

CARBIDOPA ANHYDROUS

25 mg

Carbidopa

LEVODOPA

250 mg

Levodopa

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TIDOMET FORTE TABLET - HSA Approval | MedPath